BEA-17

Uppsala, Sweden – September 22, 2026 -- Beactica Therapeutics AB has initiated IND-enabling studies for BEA-17, a first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST, moving the glioblastoma therapy toward first-in-human trials.

Beactica targets a cancer with 15-month median survival and no new treatment in over two decades

Glioblastoma remains the most common and aggressive primary brain tumour, with a median overall survival of approximately 15 months. Standard of care has stayed essentially unchanged for more than 20 years, and immunotherapies successful against other cancers have consistently failed against GBM's immunosuppressive tumour microenvironment.